ArticleJournal of assisted reproduction and genetics2025
Ongoing pregnancy rate is associated with trigger-day progesterone level in letrozole/clomiphene intrauterine insemination cycles.
Article in Journal of assisted reproduction and genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePrior studies in fresh embryo transfer IVF cycles have associated elevated serum progesterone level on day of ovulatory trigger, particularly if ≥ 1.5 ng/ml, with decreased pregnancy rates. A similar association has been found in intrauterine insemination (IUI) cycles using gonadotropins for ovulation induction. The purpose of this study was to evaluate the association of trigger-day progesterone level with pregnancy rates in IUI cycles using oral ovulation induction agents.
methodsA retrospective cohort study was conducted at a multicenter private practice. 4,866 IUI cycles using letrozole or clomiphene were analyzed from January 1, 2017, to December 31, 2023. The primary outcome measure was ongoing pregnancy per cycle as a function of the serum progesterone level obtained on the day of ovulatory trigger. Secondary outcome measures were positive pregnancy, clinical pregnancy, and pregnancy loss.
resultsWhen compared to cycles with trigger-day progesterone < 1 ng/ml, ongoing pregnancy was significantly lower when progesterone was ≥ 1.5 ng/ml (11.9% versus 5.6%; Risk Ratio (RR) 0.46 (95% CI 0.25-0.84)). Ongoing pregnancy was comparable when progesterone was < 1 ng/ml or 1-1.49 ng/ml (11.9% versus 9.2%; (RR 0.75 (95% CI 0.55-1.03)). Positive pregnancy and clinical intrauterine pregnancy outcomes were also significantly lower in the ≥ 1.5 ng/ml versus < 1 ng/ml group, but comparable in the < 1 ng/ml and 1-1.49 ng/ml groups. Pregnancy loss was not significantly different between groups.
conclusionPregnancy outcomes are optimized when trigger-day progesterone level is < 1.5 ng/ml in IUI cycles using oral ovulation induction agents, highlighting the value of obtaining a progesterone level on the day of ovulatory trigger.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.